Literature DB >> 20975063

Clinical implications of the cancer genome.

Laura E Macconaill1, Levi A Garraway.   

Abstract

Cancer is a disease of the genome. Most tumors harbor a constellation of structural genomic alterations that may dictate their clinical behavior and treatment response. Whereas elucidating the nature and importance of these genomic alterations has been the goal of cancer biologists for several decades, ongoing global genome characterization efforts are revolutionizing both tumor biology and the optimal paradigm for cancer treatment at an unprecedented scope. The pace of advance has been empowered, in large part, through disruptive technological innovations that render complete cancer genome characterization feasible on a large scale. This article highlights cardinal biologic and clinical insights gleaned from systematic cancer genome characterization. We also discuss how the convergence of cancer genome biology, technology, and targeted therapeutics articulates a cohesive framework for the advent of personalized cancer medicine.

Entities:  

Mesh:

Year:  2010        PMID: 20975063      PMCID: PMC3020694          DOI: 10.1200/JCO.2009.27.4944

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  86 in total

1.  PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Kaori Shima; Natsumi Irahara; Shoko Kure; Andrew T Chan; Jeffrey A Engelman; Peter Kraft; Lewis C Cantley; Edward L Giovannucci; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2009-02-23       Impact factor: 44.544

2.  Next-generation DNA sequencing.

Authors:  Jay Shendure; Hanlee Ji
Journal:  Nat Biotechnol       Date:  2008-10       Impact factor: 54.908

3.  Rapid whole-genome mutational profiling using next-generation sequencing technologies.

Authors:  Douglas R Smith; Aaron R Quinlan; Heather E Peckham; Kathryn Makowsky; Wei Tao; Betty Woolf; Lei Shen; William F Donahue; Nadeem Tusneem; Michael P Stromberg; Donald A Stewart; Lu Zhang; Swati S Ranade; Jason B Warner; Clarence C Lee; Brittney E Coleman; Zheng Zhang; Stephen F McLaughlin; Joel A Malek; Jon M Sorenson; Alan P Blanchard; Jarrod Chapman; David Hillman; Feng Chen; Daniel S Rokhsar; Kevin J McKernan; Thomas W Jeffries; Gabor T Marth; Paul M Richardson
Journal:  Genome Res       Date:  2008-09-04       Impact factor: 9.043

4.  Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.

Authors:  Jose Lutzky; Juergen Bauer; Boris C Bastian
Journal:  Pigment Cell Melanoma Res       Date:  2008-05-29       Impact factor: 4.693

5.  Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.

Authors:  Claudia Scholl; Stefan Fröhling; Ian F Dunn; Anna C Schinzel; David A Barbie; So Young Kim; Serena J Silver; Pablo Tamayo; Raymond C Wadlow; Sridhar Ramaswamy; Konstanze Döhner; Lars Bullinger; Peter Sandy; Jesse S Boehm; David E Root; Tyler Jacks; William C Hahn; D Gary Gilliland
Journal:  Cell       Date:  2009-05-29       Impact factor: 41.582

6.  Somatic mutations affect key pathways in lung adenocarcinoma.

Authors:  Li Ding; Gad Getz; David A Wheeler; Elaine R Mardis; Michael D McLellan; Kristian Cibulskis; Carrie Sougnez; Heidi Greulich; Donna M Muzny; Margaret B Morgan; Lucinda Fulton; Robert S Fulton; Qunyuan Zhang; Michael C Wendl; Michael S Lawrence; David E Larson; Ken Chen; David J Dooling; Aniko Sabo; Alicia C Hawes; Hua Shen; Shalini N Jhangiani; Lora R Lewis; Otis Hall; Yiming Zhu; Tittu Mathew; Yanru Ren; Jiqiang Yao; Steven E Scherer; Kerstin Clerc; Ginger A Metcalf; Brian Ng; Aleksandar Milosavljevic; Manuel L Gonzalez-Garay; John R Osborne; Rick Meyer; Xiaoqi Shi; Yuzhu Tang; Daniel C Koboldt; Ling Lin; Rachel Abbott; Tracie L Miner; Craig Pohl; Ginger Fewell; Carrie Haipek; Heather Schmidt; Brian H Dunford-Shore; Aldi Kraja; Seth D Crosby; Christopher S Sawyer; Tammi Vickery; Sacha Sander; Jody Robinson; Wendy Winckler; Jennifer Baldwin; Lucian R Chirieac; Amit Dutt; Tim Fennell; Megan Hanna; Bruce E Johnson; Robert C Onofrio; Roman K Thomas; Giovanni Tonon; Barbara A Weir; Xiaojun Zhao; Liuda Ziaugra; Michael C Zody; Thomas Giordano; Mark B Orringer; Jack A Roth; Margaret R Spitz; Ignacio I Wistuba; Bradley Ozenberger; Peter J Good; Andrew C Chang; David G Beer; Mark A Watson; Marc Ladanyi; Stephen Broderick; Akihiko Yoshizawa; William D Travis; William Pao; Michael A Province; George M Weinstock; Harold E Varmus; Stacey B Gabriel; Eric S Lander; Richard A Gibbs; Matthew Meyerson; Richard K Wilson
Journal:  Nature       Date:  2008-10-23       Impact factor: 49.962

7.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.

Authors:  Charles G Mullighan; Xiaoping Su; Jinghui Zhang; Ina Radtke; Letha A A Phillips; Christopher B Miller; Jing Ma; Wei Liu; Cheng Cheng; Brenda A Schulman; Richard C Harvey; I-Ming Chen; Robert J Clifford; William L Carroll; Gregory Reaman; W Paul Bowman; Meenakshi Devidas; Daniela S Gerhard; Wenjian Yang; Mary V Relling; Sheila A Shurtleff; Dario Campana; Michael J Borowitz; Ching-Hon Pui; Malcolm Smith; Stephen P Hunger; Cheryl L Willman; James R Downing
Journal:  N Engl J Med       Date:  2009-01-07       Impact factor: 91.245

8.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

9.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

10.  Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing.

Authors:  Andreas Gnirke; Alexandre Melnikov; Jared Maguire; Peter Rogov; Emily M LeProust; William Brockman; Timothy Fennell; Georgia Giannoukos; Sheila Fisher; Carsten Russ; Stacey Gabriel; David B Jaffe; Eric S Lander; Chad Nusbaum
Journal:  Nat Biotechnol       Date:  2009-02-01       Impact factor: 54.908

View more
  79 in total

1.  An emerging toolkit for targeted cancer therapies.

Authors:  Gordon B Mills
Journal:  Genome Res       Date:  2012-02       Impact factor: 9.043

Review 2.  Recent progress and clinical importance on pharmacogenetics in cancer therapy.

Authors:  Thomas I Peng Soh; Wei Peng Yong; Federico Innocenti
Journal:  Clin Chem Lab Med       Date:  2011-09-28       Impact factor: 3.694

3.  Precision medicine in diffuse large B-cell lymphoma: hitting the target.

Authors:  Joost S Vermaat; Steven T Pals; Anas Younes; Martin Dreyling; Massimo Federico; Igor Aurer; John Radford; Marie José Kersten
Journal:  Haematologica       Date:  2015-08       Impact factor: 9.941

Review 4.  Advances in the Molecular Analysis of Soft Tissue Tumors and Clinical Implications.

Authors:  Adrian Marino-Enriquez
Journal:  Surg Pathol Clin       Date:  2015-09

Review 5.  Implementing personalized cancer care.

Authors:  Richard L Schilsky
Journal:  Nat Rev Clin Oncol       Date:  2014-04-01       Impact factor: 66.675

6.  High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes.

Authors:  Edwin Choy; Francis Hornicek; Laura MacConaill; David Harmon; Zeeshan Tariq; Levi Garraway; Zhenfeng Duan
Journal:  Cancer       Date:  2011-10-17       Impact factor: 6.860

7.  Returning a Genomic Result for an Adult-Onset Condition to the Parents of a Newborn: Insights From the BabySeq Project.

Authors:  Ingrid A Holm; Amy McGuire; Stacey Pereira; Heidi Rehm; Robert C Green; Alan H Beggs
Journal:  Pediatrics       Date:  2019-01       Impact factor: 7.124

8.  First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer.

Authors:  Ya-Chen Tina Shih; Ying Xu; Wenli Dong; Fabrice Smieliauskas; Sharon Giordano; Yu Shen
Journal:  Breast Cancer Res Treat       Date:  2014-02-21       Impact factor: 4.872

Review 9.  Advancing precision medicine for prostate cancer through genomics.

Authors:  Sameek Roychowdhury; Arul M Chinnaiyan
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

Review 10.  Existing and emerging technologies for tumor genomic profiling.

Authors:  Laura E MacConaill
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.